financetom
Business
financetom
/
Business
/
Grocery Giant Kroger CFO Raises Identical Sales Outlook, But Maintains Caution Due To Tariff Uncertainty
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Grocery Giant Kroger CFO Raises Identical Sales Outlook, But Maintains Caution Due To Tariff Uncertainty
Jun 20, 2025 8:51 AM

Kroger Co. ( KR ) shares rose on Friday after the grocer topped Q1 earnings estimates, boosted margins, and reaffirmed its full-year outlook.

The company reported first-quarter adjusted earnings per share of $1.49, beating the analyst consensus estimate of $1.46. Quarterly sales of $45.12 billion missed the Street view of $45.19 billion, with identical sales ex-fuel increasing 3.2%.

The strong earnings came even as Kroger ( KR ) faced a viral backlash on TikTok, where a video showing minimally decorated Juneteenth cakes at an Atlanta store drew criticism for what many called a tone-deaf tribute to a holiday celebrating Black liberation, USA Today reports.

Also Read: Olive Garden Parent Darden Records Strong Q4 Growth, Hikes Dividend

Meanwhile, operating profit in the quarter under review increased to $1.322 billion from $1.294 billion a year ago.

Gross margin in the quarter under review increased to 23% from 22% a year ago. The improvement in gross margin was primarily attributable to the sale of Kroger Specialty Pharmacy, lower shrink, and lower supply chain costs, partially offset by the mix effect from growth in pharmacy sales which have lower margins.

The FIFO gross margin rate increased by 79 basis points, including a 46 basis point boost from the sale of Kroger Specialty Pharmacy.

The improvement in rate was primarily attributable to the sale of Kroger Specialty Pharmacy, lower shrink and lower supply chain costs, partially offset by the mix effect from growth in pharmacy sales which have lower margins.

Kroger ( KR ) took a $100 million charge in the first quarter for closing around 60 stores over 18 months.

The move is expected to bring “modest financial benefit,” which will be reinvested in the customer experience and won’t affect full-year guidance. All affected employees will be offered roles at other locations.

During the fourth quarter of Kroger’s fiscal 2024, Kroger ( KR ) entered into a $5 billion accelerated share repurchase program (ASR), which is expected to be completed by Kroger’s fiscal third quarter of 2025.

After completion of the ASR program, Kroger ( KR ) expects to resume open market share repurchases under the remaining $2.5 billion authorization. Kroger ( KR ) expects to complete these open market share repurchases by the end of fiscal 2025.

The company exited the quarter with total cash worth $340 million and temporary cash investments worth $4.398 billion.

Long-term debt (including obligations under finance leases) expanded to $17.138 billion, compared with $12.021 billion a year ago.

“Our strong sales results and positive momentum give us confidence to raise our identical sales ex-fuel guidance, to a new range of 2.25% to 3.25%. While first-quarter sales and profitability exceeded our expectations, the macroeconomic environment remains uncertain, and as a result, other elements of our guidance remain unchanged,” CFO David Kennerley said.

He expressed continued confidence in the company’s strategy and added, “We continue to believe that our strategy focusing on fresh, Our Brands and eCommerce will continue to resonate with customers, and our resilient model positions us well to navigate the current environment.”

Outlook

Kroger ( KR ) reaffirmed its fiscal 2025 adjusted EPS guidance of $4.60 to $4.80, compared with the $4.75 analyst estimate.

The company raised identical sales ex-fuel outlook to 2.25%-3.25% versus the prior view of 2%-3%.

Price Action: KR shares are trading higher by 8.97% to $71.40 at last check Friday.

Read Next:

This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US Supreme Court to Review Mexico's Lawsuit Against Smith & Wesson
US Supreme Court to Review Mexico's Lawsuit Against Smith & Wesson
Oct 4, 2024
11:38 AM EDT, 10/04/2024 (MT Newswires) -- The Supreme Court will consider rejecting a lawsuit filed in a US court by Mexico's government alleging that Smith & Wesson (SWBI) and other companies facilitate gun sales to people linked to the country's drug cartels, court documents showed Friday. The Supreme Court will hear company arguments that the suit filed by Mexico...
Diamondback Energy Is 'Making All The Right Moves,' Says Bullish Analyst
Diamondback Energy Is 'Making All The Right Moves,' Says Bullish Analyst
Oct 4, 2024
Diamondback Energy Inc ( FANG ) shares were climbing in early trading on Friday, during a rise in energy stocks with growing Middle East tensions. Following the Endeavor acquisition, Diamondback and ExxonMobil Corp are now the dominant players in the Midland Basin, according to BMO Capital Markets. Analyst Phillip Jungwirth upgraded the rating for Diamondback Energy ( FANG ) from...
US FDA puts Kezar Life Sciences' lupus treatment trial on hold after patient deaths
US FDA puts Kezar Life Sciences' lupus treatment trial on hold after patient deaths
Oct 4, 2024
Oct 4 (Reuters) - The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' ( KZR ) trial of experimental drug for lupus, the company said on Friday. The FDA's decision comes after the company said it had paused the mid-stage trial of the drug, zetomipzomib, to review safety data following the deaths of four...
Psyence Biomedical Says It Will Not Proceed With Clairvoyant Therapeutics Acquisition
Psyence Biomedical Says It Will Not Proceed With Clairvoyant Therapeutics Acquisition
Oct 4, 2024
04:59 PM EDT, 10/04/2024 (MT Newswires) -- Psyence Biomedical ( PBM ) said Friday it will not proceed with its proposed acquisition of Clairvoyant Therapeutics following the completion of due diligence. The company is proceeding with its phase 2b clinical study, which uses psilocybin with psychotherapy to treat Adjustment Disorder in palliative care patients diagnosed with life-limiting cancer, Psyence Biomedical...
Copyright 2023-2026 - www.financetom.com All Rights Reserved